Acapatamab
- Generic Name
- Acapatamab
Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 3
- Registration Number
- NCT04822298
- Locations
- ๐ฆ๐น
Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, Austria
๐ฆ๐นLandeskrankenhaus Salzburg, Salzburg, Austria
๐ฆ๐บChris OBrien Lifehouse, Camperdown, New South Wales, Australia
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1
Terminated
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 65
- Registration Number
- NCT04631601
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of California at Irvine Medical Center, Orange, California, United States
๐บ๐ธUniversity of California San Francisco Mission Bay Campus, San Francisco, California, United States
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Phase 1
Terminated
- Conditions
- Metastatic Castration-resistant Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 212
- Registration Number
- NCT03792841
- Locations
- ๐บ๐ธ
City of Hope at Long Beach Elm, Long Beach, California, United States
๐บ๐ธEl Camino Hospital, Campbell, California, United States
๐บ๐ธIndiana University, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath